论文信息 - Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod - 字舞流文

Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod

H. Maloni | V. Nava | Gulnaz Siddiqui

[1] J. de Seze,et al. Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection , 2021, Revue Neurologique.

[2] S. Bohlega,et al. Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia , 2021, Multiple Sclerosis and Related Disorders.

[3] P. Dormitzer,et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[4] S. Kelly,et al. COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?” , 2020, The Egyptian Journal of Neurology, Psychiatry and Neurosurgery.

[5] E. Legangneux,et al. Impact of siponimod on vaccination response in a randomized, placebo-controlled study , 2017, Neurology: Neuroimmunology & Neuroinflammation.